- Home
- SYRE vs PRAA Comparison
SYRE vs PRAA Comparison
Compare SYRE & PRAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- PRAA
- Stock Information
- Founded
- SYRE 2013
- PRAA 1996
- Country
- SYRE United States
- PRAA United States
- Employees
- SYRE N/A
- PRAA N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- PRAA Finance: Consumer Services
- Sector
- SYRE Health Care
- PRAA Finance
- Exchange
- SYRE Nasdaq
- PRAA Nasdaq
- Market Cap
- SYRE 897.9M
- PRAA 790.6M
- IPO Year
- SYRE 2016
- PRAA N/A
- Fundamental
- Price
- SYRE $12.67
- PRAA $17.01
- Analyst Decision
- SYRE Buy
- PRAA Strong Buy
- Analyst Count
- SYRE 8
- PRAA 2
- Target Price
- SYRE $50.00
- PRAA $32.00
- AVG Volume (30 Days)
- SYRE 899.5K
- PRAA 360.8K
- Earning Date
- SYRE 05-08-2025
- PRAA 05-05-2025
- Dividend Yield
- SYRE N/A
- PRAA N/A
- EPS Growth
- SYRE N/A
- PRAA N/A
- EPS
- SYRE N/A
- PRAA 1.79
- Revenue
- SYRE N/A
- PRAA $1,114,524,000.00
- Revenue This Year
- SYRE N/A
- PRAA $7.67
- Revenue Next Year
- SYRE N/A
- PRAA $5.67
- P/E Ratio
- SYRE N/A
- PRAA $9.50
- Revenue Growth
- SYRE N/A
- PRAA 38.87
- 52 Week Low
- SYRE $10.91
- PRAA $15.94
- 52 Week High
- SYRE $40.49
- PRAA $28.64
- Technical
- Relative Strength Index (RSI)
- SYRE 36.18
- PRAA 38.40
- Support Level
- SYRE $12.04
- PRAA $16.47
- Resistance Level
- SYRE $13.29
- PRAA $17.70
- Average True Range (ATR)
- SYRE 1.27
- PRAA 1.29
- MACD
- SYRE 0.01
- PRAA -0.22
- Stochastic Oscillator
- SYRE 26.02
- PRAA 17.63
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
About PRAA PRA Group Inc.
PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.